“

These resources are needed promptly to immediately secure supply of highly effective oral antiviral treatments; to purchase monoclonal antibodies and pre-exposure prophylaxis; to continue operating critical testing initiatives and funding testing, treatments and vaccines for the uninsured; to initiate work on a next-generation vaccine that protects against future variants; to accelerate global vaccination efforts and provide urgent humanitarian relief abroad; and for other purposes.